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Neuroblastomas derive from the arrested differentiation of neural
crest sympathoadrenal progenitor cells. Clinical evidences indi-
cate that this differentiation block is reversible, since a large
percentage of localized early-stage cancers and the majority of the
congenital disseminated forms of neuroblastoma might undergo
spontaneous regression (Siegel and Sato, 1986). On the other
hand, high-stage metastatic neuroblastomas (stages 3 and 4) are
generally less differentiated and more primitive than their
localized stages. However, high-stage neuroblastomas may differ-
entiate, as shown by the ability of their derived cell lines to acquire
neuronal cell morphology and markers. Unfortunately, patients
with advanced stage neuroblastoma have poor outcome and scarce
long-term survival, even after aggressive therapy (Pinkerton,
1993).
On the basis of these findings, it appears important to investi-
gate, in neuroblastoma, the molecular mechanisms involved in the
interplay between proliferation and differentiation. In particular,
studies on genes which have been demonstrated to play a key
function in differentiation are of pivotal relevance.
A pivotal pathway, involved in the control of proliferation/
differentiation, requires the activation of transforming growth
factor beta (TGF-b) receptors and the cascade of events which
finally results in growth impairment and differentiation. TGF-b
exerts its effect by interacting mainly with three membrane proteins
named type I (RI), type II (RII) and type III (RIII) receptors. 
TGF-bRI and TGF-bRII form a heterodimeric or heterotetrameric
complex (with one to one stoichiometry) necessary for TGF-b
signal transduction (Heldin et al, 1997), while TGF-bRIII (also
called b-glycan) is required to allow (by increasing the affinity) the
binding of TGF-bRII to the various TGF-b isoforms.
A number of studies have investigated the occurrence in human
cancers of structural and functional alterations of TGF-bRI and
TGF-bRII genes. Mutations of TGF-bRII occur in human malig-
nancies, including retinoblastoma and colon cancers and in cell
lines derived from carcinomas of the uterine cervix (Coffey et al,
1987; Kimchi et al, 1988; Lu et al, 1995; Markowitz et al, 1995).
Moreover, several investigations demonstrated a lower expression
of TGF-bRI and TGF-bRII genes in human malignancies (Kadin
et al, 1994; Matoba et al, 1998; Royuela et al, 1998; Hougaard et
al, 1999). These results have been confirmed by the observation
that the forced expression of TGF-bRI and TGF-bRII genes
remarkably reduces malignancy in the recipient cancer cell lines
(Sun et al, 1994; Wang et al, 1996).
On the other hand, to the best of our knowledge, only one study
on TGF-bRIII transcript in human cancers has been carried out.
This very recent investigation demonstrated an impairment of
TGF-bRIII expression in ovarian carcinomas (Bristow et al,
1999). In this scenario it is important to note that recently it has
also been shown that TGF-bRIII overexpression restores an
apparent unresponsiveness of breast cancer cells to the inhibitory
action of TGF-b1 (Chen et al, 1997). Thus, down-regulation of
TGF-bRIII might be an additional important mechanism of malig-
nant cells for escaping TGF-b-induced growth inhibition and
induction of differentiation.
Although TGF-b1 and TGF-b receptor genes are involved in the
control of cell differentiation and neuroblastoma development is
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far to analyse the expression of these four genes in human neuro-
blastomas. This investigation is peculiarly important in view of the
observation that neuronal tissue is responsive to TGF-b control.
Moreover, very few investigations have been performed on TGF-
bRIII expression in human tumours even though, as discussed
above, this gene might also be considered as a potential cancer
suppressor gene.
In this report, we described the first investigation on TGF-b and
TGF-b receptor (type I, II and III) gene expression in a large series
(61 specimens) of human neuroblastoma. This study was carried
out in order to evaluate the role of these genes in the development
and evolution of such a frequent paediatric tumour. The results
obtained were also compared with two other neuroblastoma
important genetic features, namely N-myc gene amplification and
1p chromosome status.
MATERIALS AND METHODS
Tumour samples
Sixty-one primary tumour samples, belonging to the Italian Tissue
Bank, were selected to represent the distribution of stages found in
neuroblastoma. Patients were staged according to the revised
INSS staging system (Brodeur et al, 1993). The resected tumours
were frozen immediately in liquid nitrogen and stored at –80°C
until analysis. Diagnosis was established by histological examina-
tion of tumour tissue obtained at surgery. In order to ensure that
tumour samples used for molecular analyses contained a sufficient
proportion of malignant cells, several cytological and histological
evaluations of each sample were performed. Thus, only samples
which were clearly demonstrated to contain more than 95%
tumour cells were used in the present study. This allowed us to rule
out the possibility that the obtained results were due to normal
cells present in the analysed specimens.
RT-PCR
Reverse transcription polymerase chain reaction (RT-PCR) 
analysis was performed using the StrataScript RT-PCR Kit
(Stratagene, La Jolla, CA, USA). Briefly, 2.5 mg of total RNA,
prepared as reported (Iolascon et al, 1998b), were reverse-tran-
scribed by StrataScript RNAase H- reverse transcriptase (25 U)
using oligo(dT) primer (150 ng) in a final volume of 25 ml. cDNA
samples were diluted tenfold in a PCR reaction assay to a volume
of 50 ml containing, in addition to the DNA template, 30 mM
Tris–HCl (pH 9.0), 50 mM potassium chloride, 1.5 mM magnesium
chloride, 200 mg of each primer, 0.2 mM of each nucleotide and
1 unit of Taq DNA polymerase. Temperature conditions and
primers for glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
were previously reported (Iolascon et al, 1998b).
Primers used for TGF-b1 were as follows: 5¢-TGTCCCCTATC-
CCCTGACTCCC-3¢, and 5¢-CCCAGCCTGGAAGGCCTCCA-
TC-3¢ (amplified fragment of 221 bp). Temperature conditions for
TGF-b1 were: hot start at 95°C for 5 min, 30 cycles composed of
steps at 95°C for 1 min, 65°C for 1 min, 72°C for 1 min and a final
elongation step at 72°C for 7 min.
Primers used for TGF-bRI were as follows: 5¢-ATTCCTCGA-
GATAGGCCGTT-3¢, and 5¢-AGGGCGATCTAATGAAGGGT-3¢
(amplified fragment of 288 bp). Temperature conditions for 
TGF-bRI were: hot start at 95°C for 5 min, 30 cycles composed of
steps at 95°C for 1 min, 58°C for 1 min, 72°C for 1 min and a final
elongation step at 72°C for 7 min.
Primers used for TGF-bRII were as follows: 5¢-TGTGTTCCT-
GTAGCTCTGATG-3¢, and 5¢-AGATCTTGACTGCCACTGTC-
TC-3¢ (amplified fragment of 432 bp). Temperature conditions for
TGF-bRII were: hot start at 94°C for 3 min, 30 cycles composed
of steps at 94°C for 1 min, 60°C for 1 min, 72°C for 1 min and 
a final elongation step at 72°C for 7 min. Primers used for 
TGF-bRIII were as follows: 5¢-TGTCACCTGGCACATTCATT-
3¢, and 5¢-TCTCAGCACTGTCTTGGTGG-3¢ (amplified frag-
ment of 246 bp). Temperature conditions for TGF-bRIII were: hot
start at 94°C for 3 min, 30 cycles composed of steps at 94°C for 
1 min, 57°C for 1 min, 72°C for 1 min and a final elongation step
at 72°C for 7 min.
Before amplification with each specific primer pairs, an aliquot
of the cDNA preparation was amplified using GAPDH primers to
determine the efficacy of the generated cDNA. Moreover, we used
five different cDNA concentrations to assure that signals (both of
GAPDH and of the analysed genes) were proportional to input
mRNA. These controls are important for comparison between
samples because they ensure that equivalent amounts of RNA 
are amplified. Finally, each experiment was performed at least in
duplicate and, in several cases, in triplicate.
Aliquots of PCR reactions were separated and analysed by elec-
trophoresis on 2% (w/v) agarose gels or non-denaturing 8% (w/v)
polyacrylamide gels (acrylamide/bisacrylamide, 29/1). In the latter
case, the amplified products were stained using silver nitrate
method. In several cases, the amplified products were recovered
from the gels and sequenced as reported in Iolascon et al (1998b).
In all cases the sequence of the amplified products corresponded to
that reported in the literature.
Immunohistochemistry
In order to evaluate the TGF-bRIII protein level, an immunohisto-
chemical study was carried out on the ten available specimes of
neuroblastoma cases already analysed by RT-PCR. The analyses
were performed on histological slides from formalin-fixed and
paraffin-embedded tumour tissues by using goat polyclonal anti-
bodies raised against the carboxyl terminus of human TGF-bRIII
(Santa Cruz, sc-6189). Deparaffinized sections underwent a
microwave exposition, in 10 mM citrate buffer, pH 6, to retrieve
antigenicity and thereafter were treated with 3% hydrogen
peroxide for endogenous peroxidase inactivation. After incubation
for 30 min at room temperature with 1:1000 dilution of primary
antibody, the reaction was underscored using a 1:500 diluted rabbit
anti-goat antibody at room temperature for 30 min. The immuno-
complexes were visualized by using the Envision system (Dako)
following manufacturer’s instructions. Colourimetric reaction was
accomplished using diamminobenzidine as a chromogen.
RESULTS
Table 1 reports the stage classification and some genetic features of
the neuroblastomas analysed. A total of 61 different specimens
were studied, classified into five stages (1–4 and 4S) on the basis of
well established clinical criteria. In particular, our investigation
involved nine tumours of stage 1, ten of stage 2, nine of stage 3, 28
of stage 4 and five of stage 4S. A large percentage of the specimens
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Table 1 Expression of TGF-b1 and TGF-b receptor type I, II and III genes in human neuroblastoma of different stages
Sample no. TGF-bRI TGF-bRII TGF-bRIII TGF-b1 GAPDH N-myc 1p status
Stage 4S
586 + + ++ + + 1 Undel.
809 +++ +++ ++ + + 1 Tripl./undel.
912 +++ ++ ++ – + 1 Undel.
803 +++ +++ ++ ++ + 1 Tripl./undel.
887 +++ +++ + + + 1 –
Stage 1
655 – + +++ ND + 1 Undel.
591 +++ ++ ++ + + 1 Undel.
823 +++ +++ + + + 1 Undel.
776 +++ – ++ – + 1 Undel.
772 – + + + + 1 Dipl./del.
806 +++ – ++ – + 1 Tripl./del.
859 – – ++ + + 1 Tripl./undel.
916 + + ++ ++ + 1 –
778 +++ ++ – + + 1 Del.
Stage 2
606 +++ + + + + 1 Undel.
652 +++ ++ + + + 1 Undel.
647 +++ ++ + + + 1 Undel.
634 +++ +++ + + + 1 Undel.
852 +++ + + – + 1 Undel.
851 +++ ++ ++ – + 1 Undel.
762 + – – – + 1 Tripl./undel.
764 +++ + – – + 1 Undel.
656 + ++ – – + 1 Undel.
626 +++ +++ ++ + + 1 Undel.
Stage 3
619 +++ + – + + 13 Del. 1p32–36
579 +++ + – – + 1 Undel.
592 +++ – – – + 12 Del. 1p32–36
572 + ++ – + + 1 Del 1p32
858 + + – + + 1 Tripl./undel.
802 +++ + – + 60 Dipl./undel.
799 +++ + ++ +++ 1 Undel.
793 +++ ++ – + + 1 Undel.
698 + +++ ++ + + 1 –
Stage 4
687 – – – + + 20 Undel.
640 +++ ++ – + + 1 Undel.
691 + +++ – ++ + 1 Undel.
651 – – – + + 7 Del. 1p32–36
945 ND +++ ++ ND + Ampl. Undel.
718 +++ +++ + + + 1 –
811 +++ +++ + + + 1 Undel.
870 + – – + + 1 –
871 +++ +++ – + + 1 Undel.
872 +++ +++ + +++ + 1 Tetr./undel.
876 +++ +++ + + + 1 Undel.
882 ++ +++ ++ +++ + 1 Tripl./undel.
701 +++ +++ ++ + + 1 –
846 +++ ++ – – + 1 Undel.
728 ND + + ND + 1 Undel.
780 + ++ – + + 1 Undel.
837 +++ ++ – + + 1 Undel.
834 +++ ++ – + + 1 Del.
321 +++ +++ – + + Ampl. Del.
292 ++ ++ – +++ + Ampl. Del.
505 +++ +++ – + + Ampl. Del.
350 +++ ++ – + + Ampl. –
690 +++ +++ – + + Ampl. Del.
664 +++ ++ – + + Ampl. Del.
597 + ++ – + + Ampl. –
753 +++ ++ – + + Ampl. –
651 +++ ++ – +++ + Ampl. –
644 +++ ++ – + + Ampl. –
N-myc reports the number of copies of the gene or if the gene is amplified. The symbols –, +, ++ and +++ represent the relative amount of the PCR product
estimated by laser scanner analysis. These results were generally a mean of three different experiments. Del., deleted; Ampl., amplified; Tetr., ternary; Tripl.,
triplicate; Undel., undeleted.were previously investigated for N-myc gene amplification and
genetic alteration at 1p level (Iolascon et al, 1998c). Each cancer
sample was analysed for the expression of TGF-b1, TGF-bRI,
TGF-bRII and TGF-bRIII genes by means of RT-PCR method-
ology. Ten specimens were also studied by immunohistochemistry
for TGF-bRIII protein.
Expression of TGF-b1 gene and of TGF-bRI, -RII
and -RIII genes
Figure 1 shows examples of TGF-b1, TGF-bRI, TGF-bRII and
TGF-bRIII gene expression analysed by means of RT-PCR in
some neuroblastoma specimens.
TGF-b1 mRNA occurred in neuroblastomas of all stages with
small variations (from 60% to 90% of samples from different
stages) (Table 1). The gene encoding TGF-bRI and TGF-bRII was
expressed in all neuroblastomas of stage 4S and in the majority of
specimens belonging to the other stages, including particularly
those of stage 4 (Table 1).
The analysis of the transcription of TGF-bRIII gene in stage 4S
cancers showed that all specimens (100%) presented the expres-
sion of the gene (Table 1). When we investigated TGF-bRIII
mRNA in the other neuroblastoma samples we observed an enor-
mous decrease from stage 1 (89%) and stage 2 (70%) to stage 3
(23%) and stage 4 (29%). Importantly, almost all (12 out of 13,
92%) stage 4 and all (three out of three, 100%) stage 3 cancers
with N-myc-amplified gene did not express TGF-bRIII gene.
Immunohistochemistochemical analyses
Table 2 reports the results of the immunohistochemical investiga-
tion carried out on ten specimens of neuroblastoma. We analysed
two samples of neuroblastomas of stage 4S, three of stage 1, one of
stages 2 and 3 respectively, and three specimens of stage 4. In the
last case, we studied one sample containing high levels of TGF-
bRIII gene mRNA and two specimens that do not contain this
mRNA. The data obtained, which were reported as percentage of
positive cells, strongly confirm, at protein level, the results of RT-
PCR studies. Figure 2 shows examples of two neuroblastoma
samples analysed by specific TGF-bRIII antibodies. It is evident
from the images the occurrence of strong signals, in the positive
cells, at cellular membrane level.
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Figure 1 Analysis of TGF-b1, TGF-bRI, TGF-bRII and TGF-bRII mRNA in
human neuroblastoma specimens. Total RNA (2.5 mg) was reverse
transcribed as described under Materials and Methods. cDNA samples were
then diluted in a PCR assay and amplified by specific primers. Aliquots of
PCR reaction (5 ml) were separated by non-denaturing 8% polyacrylamide gel
and stained by silver nitrate method. Finally, the relative amount of each
amplified product was determined by densitometric scanner. From the top to
the bottom: TGF-b1 gene, TGF-bRII gene TGF-bRI, TGF-bRIII gene and
GAPDH gene. Numbers reported at the top of panels represent samples
examined
Figure 2 Immunochemical analysis of TGF-bRIII protein in human
neuroblastoma samples. Specimens of neuroblastomas showing high level of
TGF-bRIII protein (A, sample no. 912) or the absence of the receptor (B,
sample no. 651). Details on the immunochemical staining technique are
reported in Materials and Methods
Table 2 mRNA and protein TGF-bRIII level in human neuroblastoma of
different stages
Sample no. TGF-bRIII TGF-bRIII protein
mRNAa (% of positive cells)b
Stage 4S
809 ++ >75
912 ++ >75
Stage 1
806 ++ >75
859 ++ >75
778 – <20
Stage 2 – Absent
764
Stage 3 – Absent
802
Stage 4
651 – Absent
690 – <10
882 ++ >70
aDetermined by RT-PCR. bDetermined by immunochemical methodologies.DISCUSSION
Cell growth and differentiation are two fundamental aspects of
multicellular existence and, intertwined with these processes, is
the phenomenon of unlimited growth, which is the basis of the
neoplastic state. Indeed, cancer might be envisaged as the result of
unregulated proliferation of a given cell, frequently due to a block
of its ability to undergo differentiation. The present paper reports
the results of a study aimed to investigate the expression, in human
neuroblastomas, of genes involved in the regulation of TGF-b
pathway which plays a key role in the control of the molecular
interplay between proliferation and differentiation. All the
analysed samples contained more than 95% malignant cells, thus
our findings were not (or scarcely) influenced by the occurrence of
normal cells in the specimens.
Although TGF-b is one of the most potent inhibitors of cell
growth, several malignancies of different origin are resistant to
TGF-b, suggesting that the developing of unresponsiveness to this
molecule plays an important role in cancerogenesis (Polyak,
1966). Tumours acquire resistance to TGF-b relatively late during
malignant progression and this appears to be associated with
developing invasiveness (Filmus and Kerbel, 1993; Fynan and
Reiss, 1993). Although the loss of TGF-bRII has been reported in
retinoblastomas and certain colon carcinoma cell lines (Coffey 
et al, 1987; Kimchi et al, 1988), it occurs quite infrequently.
Conversely, decreased expression of TGF-bRII has been
frequently observed in human tumours and cell lines (Filmus et al,
1992; Kadin et al, 1994; Matoba et al, 1998; Royuela et al, 1998;
Hougaard at al, 1999), and this phenomenon may result in resis-
tance to TGF-b growth inhibitory activity. When we analysed 
the TGF-bRII gene expression in human neuroblastomas, we
observed that all the neoplasias of stage 4S and the large majority
of neuroblastomas of the other stages expressed this specific tran-
script (Table 1). Thus, these results argue against down-regulation
of TGF-bRII expression as an important factor in neuroblastoma
development and/or progression. Moreover, no remarkable varia-
tion in the expression of TGF-bRI (and of TGF-b1) gene was
observable in tumours of different stages.
Very recently it has been demonstrated that TGF-bRIII is also
critical in the response to various TGF-b isoforms, and that its
overexpression might restore the growth inhibitory effect of TGF-
b in the presence of low level TGF-bRII (Chen et al, 1997). Thus,
the membrane content of TGF-bRIII is important in TGF-b growth
control.
Our results show that TGF-bRIII gene expression is signifi-
cantly reduced in neuroblastomas of stage 3 and 4. Conversely, all
cancers of stage 4S (which spontaneoulsy undergo differentiation)
and most stage 1 and 2 tumours express remarkable levels of the
TGF-bRIII mRNA. These findings were obtained by employing a
quantitative RT-PCR technique and confirmed (on the available
samples) by direct immunohistochemical analysis. Thus, the data
reported in the present paper demonstrate, for the first time, that
neuroblastomas with a worst prognosis and high invasiveness
show down-regulation of TGF-bRIII gene transcription. Although
the molecular mechanism responsible for this phenomenon is not
known and is currently under investigation, it is totally conceiv-
able that the absence of TGF-bRIII might result in an escape of
TGF-b antiproliferative action.
TGF-bRIII (also known as b-glycan) gene belongs to a growth
factor receptor category which is not coupled to cytoplasmatic
structures involved in signalling pathways. This family also
includes the p75 gene (encoding a low affinity receptor for nerve
growth factor and neurotrophins) (Johnson et al, 1986; Radeke et
al, 1987), syndecan and other proteoglycans (whose heparin
sulphate chains bind fibroblast growth factors) (Saunders et al,
1989; Kiefer et al, 1990) and the type II receptor for insulin-like
growth factors (Morgan et al, 1987; MacDonald et al, 1988). These
molecules are of lower affinity and are generally more abundant
than the corresponding signalling receptors, properties that might
allow them to act as enhancers of growth factor access to the
receptors (Lòpez-Casillas et al, 1993). b-glycan is a membrane
proteoglycan with heparin and chondrotin sulphate chains attached
to a 100 kDa core protein (Lòpez-Casillas et al, 1991; Wang et al,
1991). This protein forms a ternary complex with a TGF-b mole-
cule and the TGF-bRII (Lòpez-Casillas et al, 1993) and increases
receptor binding affinity and cell responsiveness to TGF-b
(Lòpez-Casillas et al, 1993). For example, in the absence of b-
glycan, TGF-bRII binds TGF-b1 with a low affinity (KD of 0.5 nM)
and no detectable affinity for TGF-b2 (Lòpez-Casillas et al, 1993).
Conversely, the complex TGF-bRII–TGF-bRIII has an affinity for
TGF-b (both type 1 and type 2) in the physiological range (50 pM
and lower). Subsequently, the TGF-bRII–TGF-b dimer leaves
TGF-bRIII and associates with TGF-bRI forming a ternary
complex which activates the signalling pathway. This mechanism
establishes that b-glycan membrane level is a direct modulator of
TGF-b access to the signalling receptor.
It is well established that retinoic acid induces neuroblastoma
cell line differentiation. Moreover, clinical trials are under devel-
opment in order to evaluate the therapeutical utility in neuroblas-
toma treatment of retinoic acid and its analogues. It has previously
been demonstrated that retinoic-dependent neuroblastoma cell line
differentiation is strictly associated with TGF-b secretion and up-
regulation of all the TGF-b receptor forms (Cohen et al, 1995).
This finding supports the view that the presence of an efficacious
TGF-b response is important in neuroblastoma differentiation and
that its loss might play a role in the establishment of high-stage
neoplasias. Accordingly it is interesting that stage 4S neuro-
blastomas, which spontaneously evolve towards a differentiated
phenotype, express all TGF-b receptor genes (Table 1). It is also
intriguing that almost all neuroblastomas (14 out of 15 samples,
94%) with N-myc gene amplification (a well established marker of
worst evolution) show absence of TGF-bRIII gene expression
(Table 1). This result suggests a possible correlation between N-
myc overexpression and reduced TGF-b response also in view of
the observation that retinoic acid treatment of neuroblastoma cell
lines causes a down-regulation of N-myc expression and induction
of TGF-b receptor expression (Cohen et al, 1995). Future studies
will be devoted to investigating the existence of this interesting
relationship.
In conclusion, our studies suggest the possible occurrence of an
impairment of TGF-b response in neuroblastomas of stage 3 and 4,
due to specific down-regulation of TGF-bRIII gene expression. It
is to be stressed that the present study confirms and remarkably
extends the only previous observation showing the absence of
TGF-bRIII in human tumours (Bristow et al, 1999), thus leading to
the proposal of a completely novel mechanism for escaping TGF-
b growth inhibitory activity in malignancies.
Due to the increasing relevance of TGF-b-dependent pathway
aberrations in human tumorigenesis, further studies are required to
evaluate the level and activity of other components, particularly
DPC4 (SMAD4) and SMAD2 (White, 1998), in human neuro-
blastomas.
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